Ensaios clínicos de DPOC em Geórgia
12 estudos para DPOC estão buscando participantes em locais em Geórgia.
Cidades em Geórgia
Texto oficial do estudo (Inglês)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
RecrutandoFase 2
Idades de 40 a 85 · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07684820A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
RecrutandoFase 4
Idades de 40 a 85 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
RecrutandoFase 3
Idades de 40 a 80 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
RecrutandoFase 3
Idades de 40 a 80 · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT07190222A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
RecrutandoFase 3
Idades de 40 a 80 · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06883305A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- e mais 1
RecrutandoFase 3
Idades de 40 a 80 · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06878261A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
RecrutandoFase 2/3
Idades de 35 a 80 · Todos os sexos · Atualizado em 31 de ago. de 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
RecrutandoFase 3
Idades de 40 a 80 · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT06283966eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
RecrutandoFase 3
Idades de 40 a 75 · Todos os sexos · Atualizado em 28 de jul. de 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
RecrutandoFase 2
Idades de 35 a 89 · Todos os sexos · Atualizado em 15 de mai. de 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- e mais 1
RecrutandoFase 3
Idades de 40 a 80 · Todos os sexos · Atualizado em 9 de abr. de 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
RecrutandoEstudo observacional
Idades 50 e acima · Todos os sexos · Atualizado em 5 de ago. de 2025 · NCT06122077Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.